Global cancer statistics, 2012
Lindsey A. Torre,Freddie Bray,Rebecca L. Siegel,Jacques Ferlay,Joannie Lortet-Tieulent,Ahmedin Jemal +5 more
Reads0
Chats0
TLDR
A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests.Abstract:
Cancer constitutes an enormous burden on society in more and less economically developed countries alike. The occurrence of cancer is increasing because of the growth and aging of the population, as well as an increasing prevalence of established risk factors such as smoking, overweight, physical inactivity, and changing reproductive patterns associated with urbanization and economic development. Based on GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide. Over the years, the burden has shifted to less developed countries, which currently account for about 57% of cases and 65% of cancer deaths worldwide. Lung cancer is the leading cause of cancer death among males in both more and less developed countries, and has surpassed breast cancer as the leading cause of cancer death among females in more developed countries; breast cancer remains the leading cause of cancer death among females in less developed countries. Other leading causes of cancer death in more developed countries include colorectal cancer among males and females and prostate cancer among males. In less developed countries, liver and stomach cancer among males and cervical cancer among females are also leading causes of cancer death. Although incidence rates for all cancers combined are nearly twice as high in more developed than in less developed countries in both males and females, mortality rates are only 8% to 15% higher in more developed countries. This disparity reflects regional differences in the mix of cancers, which is affected by risk factors and detection practices, and/or the availability of treatment. Risk factors associated with the leading causes of cancer death include tobacco use (lung, colorectal, stomach, and liver cancer), overweight/obesity and physical inactivity (breast and colorectal cancer), and infection (liver, stomach, and cervical cancer). A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests.read more
Citations
More filters
Journal ArticleDOI
Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis
Samuel G. Smith,Samuel G. Smith,Ivana Sestak,Alice S. Forster,A.H. Partridge,Lucy Side,Michael S. Wolf,Rob Horne,Jane Wardle,Jack Cuzick +9 more
TL;DR: Low uptake of all agents and poor long-term persistence in breast cancer preventive therapy demonstrated that only 1 in 6 eligible women decided to take preventive therapy, limiting the preventive effect in women.
Journal ArticleDOI
Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
Xiaobing Qin,Shaorong Yu,Leilei Zhou,Meiqi Shi,Yong Hu,Xiaoyue Xu,Bo Shen,Siwen Liu,Dali Yan,Jifeng Feng +9 more
TL;DR: This study provides new insights into the molecular mechanism of DDP resistance in lung cancer, and downregulated miR-100–5p was proved to be involved in D DP resistance in A549 cells, and mammalian target of rapamycin (mTOR) expression was reverse regulated by miR–100-5p.
Journal ArticleDOI
Surface Nanopore Engineering of 2D MXenes for Targeted and Synergistic Multitherapies of Hepatocellular Carcinoma.
TL;DR: This work provides a novel strategy for efficiently combating HCC by developing MXene‐based composite nanoplatforms, and paves a new way for extending the biomedical applications of MXenes by surface‐nanopore engineering.
Journal ArticleDOI
PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis
Lihu Gu,Manman Chen,Dongyu Guo,Hepan Zhu,Wenchao Zhang,Junhai Pan,Xin Zhong,Xinlong Li,Haoran Qian,Xianfa Wang +9 more
TL;DR: The results of this meta-analysis suggest that GC patients, specifically EBV+ and MSI, may be prime candidates for PD-1 directed therapy and support anti-PD-L1/PD-1 antibodies as a kind of immunotherapy which is promising for GC.
Journal ArticleDOI
Mesenchymal Stem Cells Promote Hepatocarcinogenesis via lncRNA-MUF Interaction with ANXA2 and miR-34a.
Xinlong Yan,Dongdong Zhang,Wei Wu,Shuheng Wu,Jingfeng Qian,Yajing Hao,Fang Yan,Pingping Zhu,Jiayi Wu,Guanling Huang,Yinghui Huang,Jianjun Luo,Xinhui Liu,Benyu Liu,Xiaomin Chen,Ying Du,Runsheng Chen,Zusen Fan +17 more
TL;DR: A lncRNA-mediated process in MSC that facilitates hepatocarcinogenesis, with potential implications for therapeutic targeting is established, and a novel lnc RNA is identified that is highly expressed in HCC tissues and correlated with poor prognosis.
References
More filters
Journal ArticleDOI
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
Jacques Ferlay,Isabelle Soerjomataram,Rajesh Dikshit,Sultan Eser,Colin Mathers,Marise Souto Rebelo,Donald Maxwell Parkin,David Forman,Freddie Bray +8 more
TL;DR: The GLOBOCAN series of the International Agency for Research on Cancer (IARC) as mentioned in this paper provides estimates of the worldwide incidence and mortality from 27 major cancers and for all cancers combined for 2012.
Journal ArticleDOI
IARC Monographs on the Evaluation of Carcinogenic Risks to Humans
TL;DR: This timely monograph is a distillation of knowledge of hepatitis B, C and D, based on a review of 1000 studies by a small group of scientists, and it is concluded that hepatitis D virus cannot be classified as a human carcinogen.
Book
Cancer Incidence in Five Continents
Freddie Bray,J. Ferlay,Mathieu Laversanne,David H. Brewster,C. Gombe Mbalawa,B. Kohler,Marion Piñeros,Eva Steliarova-Foucher,Rajaraman Swaminathan,Sebastien Antoni,Isabelle Soerjomataram,David Forman +11 more
TL;DR: The aim of this study was to establish a database of histological groups and to provide a level of consistency and quality of data that could be applied in the design of future registries.
Journal ArticleDOI
Reduced lung-cancer mortality with low-dose computed tomographic screening.
Denise R. Aberle,Amanda M. Adams,Christine D. Berg,William C. Black,Jonathan D. Clapp,Richard M. Fagerstrom,Ilana F. Gareen,Constantine Gatsonis,Pamela M. Marcus,JoRean D. Sicks +9 more
TL;DR: Screening with the use of low-dose CT reduces mortality from lung cancer, as compared with the radiography group, and the rate of death from any cause was reduced.